Osiris Therapeutics Inc. won a contract potentially worth $224.7 million from the Department of Defense (DoD) to develop its mesenchymal stem cell therapy Prochymal to treat gastrointestinal injuries resulting from radiation exposure. (BioWorld Today)
Osiris Therapeutics Inc. won a contract potentially worth $224.7 million from the Department of Defense (DoD) to develop its mesenchymal stem cell therapy Prochymal to treat gastrointestinal injuries resulting from radiation exposure. (BioWorld Today)
Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today)
Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today)
Cypress Bioscience Inc. and its partner Forest Laboratories Inc. submitted a new drug application (NDA) for milnacipran to treat fibromyalgia, a disorder characterized by pain, fatigue, muscle stiffness, cognitive dysfunction and insomnia. (BioWorld Today)
Cypress Bioscience Inc. and its partner Forest Laboratories Inc. submitted a new drug application (NDA) for milnacipran to treat fibromyalgia, a disorder characterized by pain, fatigue, muscle stiffness, cognitive dysfunction and insomnia. (BioWorld Today)
